A number of research firms have changed their ratings and price targets for BioCryst Pharmaceuticals (NASDAQ: BCRX):
- 8/6/2024 – BioCryst Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
- 8/6/2024 – BioCryst Pharmaceuticals had its price target raised by analysts at JMP Securities from $15.00 to $16.00. They now have a “market outperform” rating on the stock.
- 8/6/2024 – BioCryst Pharmaceuticals had its price target raised by analysts at Barclays PLC from $6.00 to $7.00. They now have an “equal weight” rating on the stock.
- 8/6/2024 – BioCryst Pharmaceuticals was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 8/6/2024 – BioCryst Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
BioCryst Pharmaceuticals Price Performance
Shares of NASDAQ BCRX traded up $0.02 during mid-day trading on Thursday, reaching $7.88. The company’s stock had a trading volume of 270,149 shares, compared to its average volume of 3,348,595. The firm has a market capitalization of $1.63 billion, a PE ratio of -7.36 and a beta of 1.88. The stock has a fifty day moving average of $6.89 and a two-hundred day moving average of $5.89. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.09.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million during the quarter, compared to the consensus estimate of $98.30 million. The business’s revenue was up 34.9% on a year-over-year basis. During the same period last year, the company earned ($0.24) EPS. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.
Insider Activity at BioCryst Pharmaceuticals
Institutional Investors Weigh In On BioCryst Pharmaceuticals
Several institutional investors have recently modified their holdings of BCRX. CWM LLC increased its holdings in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares during the period. Signaturefd LLC raised its position in shares of BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,599 shares in the last quarter. Quarry LP bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $54,000. Seven Eight Capital LP bought a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth $57,000. Finally, Natixis raised its position in shares of BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 9,350 shares in the last quarter. 85.88% of the stock is owned by institutional investors.
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Recommended Stories
- Five stocks we like better than BioCryst Pharmaceuticals
- Earnings Per Share Calculator: How to Calculate EPS
- Walmart Stock: Buy the Rip or Wait for the Dip?
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Stocks to Buy for a Soft Landing, If There Is One
- The Role Economic Reports Play in a Successful Investment Strategy
- Why You Shouldn’t Count Out Tencent Music Stock After Earnings
Receive News & Ratings for BioCryst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.